by A recent study conducted by researchers aimed to enhance the effectiveness of the rabies vaccine in order to combat the ongoing rabies epidemic. The study focused on the role of adjuvants, specifically molecular adjuvants that target immune cells, in improving the immune efficacy of inactivated vaccines.
The researchers constructed a recombinant virus called rCVS11-LTB, which displayed the Escherichia coli heat-labile enterotoxin B subunit (LTB) protein on the surface of viral particles. Inactivated rCVS11-LTB was found to induce higher levels of virus-neutralizing antibodies (VNAs) in both mice and dogs compared to the non-LTB expressing recombinant virus (rCVS11). Additionally, it was observed that rCVS11-LTB stimulated faster and stronger cellular immune responses and the production of CD4+ CTM in mice after immunization. Furthermore, two doses of inactivated rCVS11-LTB provided complete protection against a lethal dose of the rabies virus in mice.
These findings indicate that the recombinant virus rCVS11-LTB, which expresses the molecular adjuvant LTB, can activate high levels of both humoral and cellular immune responses in vivo. Moreover, it demonstrates promising potential as an effective inactivated rabies vaccine candidate, as it was able to provide 100% protection against rabies virus challenge in mice. This research contributes to efforts in developing improved strategies to prevent and control the spread of rabies.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
